Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients

NCT02575963 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

AML

Interventions

DRUG: Cytarabine (Phase 1 only)
BIOLOGICAL: Lintuzumab-Ac225
DRUG: Furosemide (Phase 1 only)
DRUG: Spironolactone

Sponsor

Actinium Pharmaceuticals